Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphoinositide 3-kinase (PI3K) pathway is crucial for cell functions and frequently dysregulated in cancer, promoting tumor growth.
• Small molecule inhibitors targeting PI3K, AKT, and mTOR are available but show limited clinical efficacy as monotherapies due to pathway redundancy.

Purpose of the Study:

• To explore the potential of PI3K pathway inhibitors in combination therapies for cancer.
• To identify optimal drug combinations and schedules for maximizing efficacy and minimizing toxicity.
• To define patient subpopulations likely to benefit from PI3K pathway inhibitor therapies.

Main Methods:

• Preclinical studies evaluating PI3K pathway inhibitors.
• Investigating combination therapies involving PI3K pathway inhibitors.
• Analyzing resistance mechanisms and predictive biomarkers for PI3K pathway targeted agents.

Main Results:

• PI3K pathway activation contributes to tumor growth and survival.
• Monotherapy with PI3K pathway inhibitors has shown limited clinical success.
• Pathway activation is linked to resistance to other cancer therapies.

Conclusions:

• Combination therapies involving PI3K pathway inhibitors hold potential to restore sensitivity to other agents.
• Further research is needed to optimize drug combinations, schedules, and identify predictive biomarkers.
• Defining patient subpopulations is critical for effective PI3K pathway targeted treatment strategies.